Passage Bio, Inc. Form 8-K Summary
Business context and reporting period
Passage Bio, Inc. filed a Form 8-K concerning a Nasdaq continued-listing deficiency. The report date and earliest event date were August 31, 2023; it was signed on September 1, 2023.
Key financial metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material change versus the prior period
Nasdaq notified the Company that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The notice had no immediate effect on the stock’s Nasdaq Global Select Market listing.
Guidance, outlook, risks, and contingencies
- The Company received an initial 180-calendar-day compliance period ending February 27, 2024.
- To regain compliance, the stock must close at or above $1.00 per share for at least 10 consecutive business days before the deadline.
- If the deficiency is not cured, the Company may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market, satisfies applicable requirements, and provides written notice of its intention to cure, potentially through a reverse stock split.
- If Nasdaq determines that the Company cannot cure the deficiency or is otherwise ineligible for additional time, the stock may be subject to delisting. The Company would have appeal rights, and the stock would remain listed during the appeal process.
- The Company was considering potential actions but had made no decision as of the filing. It stated that there could be no assurance it would regain compliance or satisfy other Nasdaq listing criteria.
Important facts for investors to verify
- Whether the Company regained compliance by February 27, 2024 or obtained additional compliance time.
- Whether a reverse stock split, listing transfer, appeal, or other remedial action was undertaken.
- Whether Nasdaq identified any additional listing deficiencies or ultimately initiated delisting proceedings.
- The potential effects of continued sub-$1.00 trading or a reverse stock split on the stock’s liquidity, volatility, and investor holdings.